{
  "report_rows": [
    {
      "kpi": "Adj. EPS (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$1.24 vs. cons ~$1.20",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (Q2'26, pro forma)",
      "prediction": "IN-LINE",
      "answer": "pred ~$707M vs. cons ~$704M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic growth (Q2'26)",
      "prediction": "IN-LINE",
      "answer": "pred ~+3% vs. cons ~+2.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Adj. EPS guide",
      "prediction": "BETTER",
      "answer": "guide ~$5.25-5.32 vs. cons ~$5.26 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 organic growth guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~+3-4% vs. cons ~+3.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adj. operating margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~28.4% vs. cons ~28.3% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3'26 adj. EPS / margin ramp",
      "prediction": "UNCHANGED",
      "answer": "implied EPS ~$1.35 & margin ~29% vs. cons ~$1.34 (Q3 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "China IDx divestiture (definitive agreement signed)",
      "prediction": "UNKNOWN",
      "answer": "~+100bps FY organic / ~+30bps margin uplift vs. cons 0 baked in (2H26-2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "Pharma/biotech organic growth commentary",
      "prediction": "BETTER",
      "answer": "pred ~LSD/+2-3% vs. cons ~+1-2% (Q2 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": -0.5,
  "day5_path": "FADE",
  "day5_rationale": "Stock is at 2026 highs (+37% off spring lows, +7% post-Q1) so the un-demanding ~$1.20/+2-3% bar is largely priced. A modest headline beat + China-deal confirmation likely gives a small day-1 pop, but the FY raise (if any) is limited by pro-forma re-basing and a back-half-loaded margin/software ramp, so out-period math doesn't push estimates materially higher. With positioning stretched and peer divergence narrative already in the price, expect the initial gain to fade toward flat as revisions prove muted.",
  "day5_confidence": "LOW"
}